Cite
HARVARD Citation
Bressler, B. et al. (n.d.). P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn's disease patients: results from the EVOLVE study. Journal of Crohn's and colitis. pp. S381-S382. [Online].